TGTX
TG Therapeutics, Inc.
Biotechnology · Healthcare · United States
58.08
close · 2026-10-29
value
25
cheaper than peers25
quality
85
stronger fundamentals85
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 10.09× | 55 |
| forward P/E | 21.45× | 49 |
| EV to EBITDA | 50.90× | 18 |
| price to book | 13.64× | 16 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 112.6% | 98 |
| operating margin | 17.0% | 85 |
| revenue growth | 69.6% | 73 |
| debt to equity | 129.2% | 19 |
4 of 4 measures available
Facts
| market cap | $9B |
| free cash flow | -$30.2M |
| employees | 399 |
| first trade | 2010-05-03 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-03 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.77 | 0.15 | 0.09 | -1.46 |
| free cash flow | -$25.0M | -$40.6M | -$31.4M | -$176.2M |
| net income | $447.2M | $23.4M | $12.7M | -$223.8M |
| revenue | $616.3M | $329.0M | $233.7M | $2.8M |